Loading...
•
Dec 31, 2022
Zai Lab Q4 2022 Earnings Report
Zai Lab reported a revenue increase driven by product sales and pipeline advancements.
Key Takeaways
Zai Lab Limited announced its full-year 2022 financial results, showcasing a 49.0% increase in total revenue compared to 2021, reaching $215.0 million. The company's marketed products, including ZEJULA, Optune, QINLOCK, and NUZYRA, experienced substantial sales growth. Zai Lab is preparing to launch at least 8 additional products and achieve overall corporate profitability by the end of 2025.
Total revenue increased by 41.7% to $62.6 million compared to Q4 2021.
ZEJULA achieved 55.2% year-over-year growth in product revenues.
Company expects to achieve commercial profitability this year.
Cash position of $1.0 billion as of December 31, 2022.
Zai Lab
Zai Lab
Zai Lab Revenue by Segment
Revenue by Segment
ZEJULA Revenue
CapyFin.comNUZYRA Revenue
CapyFin.com Forward Guidance
Zai Lab will focus on regulatory advancements, commercial expansion, and clinical development milestones in 2023.
Positive Outlook
- BLA approval and commercial launch for efgartigimod alfa injection for gMG.
- NDA submission to the NMPA for repotrectinib for ROS1+ advanced NSCLC.
- BLA submission to the NMPA for subcutaneous efgartigimod for gMG in mid-2023.
- ZEJULA becoming the leader in PARP inhibitors sales for ovarian cancer in China.
- Significant increase in sales of QINLOCK and NUZYRA following their inclusion on the NRDL.
Challenges Ahead
- Potential delays or rejections in regulatory approvals.
- Uncertainties in clinical trial outcomes.
- Market competition affecting product sales.
- Impact of the COVID-19 pandemic on business operations.
- Risks associated with operating in China.
Revenue & Expenses
Visualization of income flow from segment revenue to net income